EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanism of emodin in treating hepatitis B virus-associated hepatocellular carcinoma: network pharmacology and cell experiments

Yupeng Wang, Shuangxing Li, Tianqi Ren, Yikun Zhang, Bo Li, Xingchao Geng

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1458913 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Yupeng Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Chinese Academy of Medical Sciences and Peking Union M…. Hauptthemen laut MEDLINE: Emodin, Carcinoma, Hepatocellular, Molecular Docking Simulation, Liver Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatocellular carcinoma (HCC) is a pressing global issue, with Hepatitis B virus (HBV) infection remaining the primary. Emodin, an anthraquinone compound extracted from the natural plant’s. This study investigates the molecular targets and possible mechanisms of emodin in treating HBV-related HCC based on network pharmacology and molecular docking and validates the screened molecular targets through in vitro experiments.

Methods

Potential targets related to emodin were obtained through PubChem, CTD, PharmMapper, SuperPred, and TargetNet databases. Potential disease targets for HBV and HCC were identified using the DisGeNET, GeneCards, OMIM, and TTD databases. A Venn diagram was used to determine overlapping genes between the drug and the diseases. Enrichment analysis of these genes was performed using GO and KEGG via bioinformatics websites. The overlapping genes were imported into STRING to construct a protein-protein interaction network. Cytoscape 3.9.1 software was used for visualizing and analyzing the core targets. Molecular docking analysis of the drug and core targets was performed using Schrodinger. The regulatory effects of emodin on these core targets were validate through in vitro experiments.

Results

A total of 43 overlapping genes were identified. GO analysis recognized 926 entries, and KEGG analysis identified 135 entries. The main pathways involved in the KEGG analysis included cancer, human cytomegalovirus infection and prostate cancer. The binding energies of emodin with HSP90AA1, PTGS2, GSTP1, SOD2, MAPK3, and PCNA were all less than -5 kcal/mol. Compared to normal liver tissue, the mRNA levels of XRCC1, MAPK3, and PCNA were significantly elevated in liver cancer tissue. The expression levels of XRCC1, HIF1A, MAPK3, and PCNA genes were closely related to HCC progression. High expressions of HSP90AA1, TGFB1, HIF1A, MAPK3, and PCNA were all closely associated with poor prognosis in HCC. In vitro experiments demonstrated that emodin significantly downregulated the expression of HSP90AA1, MAPK3, XRCC1, PCNA, and SOD2, while significantly upregulating the expression of PTGS2 and GSTP1.

Conclusion

This study, based on network pharmacology and molecular docking validation, suggests that emodin may exert therapeutic effects on HBV-related HCC by downregulating the expression of XRCC1, MAPK3, PCNA, HSP90AA1, and SOD2, and upregulating the expression of PTGS2 and GSTP1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EmodinCarcinoma, HepatocellularMolecular Docking SimulationLiver NeoplasmsHepatitis B virusProtein Interaction MapsNetwork PharmacologyHumansComputational BiologyAntiviral AgentsHepatitis BHep G2 CellsProliferating Cell Nuclear AntigenCell ProliferationCell Line, Tumor

Stichwörter der Autor:innen

a systematic studyemodinhepatitis B virus-related hepatocellular carcinomamolecular docking validationnetwork pharmacology

Substanzen

EmodinAntiviral AgentsProliferating Cell Nuclear AntigenPCNA protein, human

Autor:innen und Institutionen

  • National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • National Center for Safety Evaluation of Drugs, National Institutes for Food and Drug Control, Beijing, China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.

Zitieren

APA

Wang, Y., Li, S., Ren, T., Zhang, Y., Li, B., & Geng, X. (2024). Mechanism of emodin in treating hepatitis B virus-associated hepatocellular carcinoma: network pharmacology and cell experiments. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1458913

Vancouver

Wang Y, Li S, Ren T, Zhang Y, Li B, Geng X. Mechanism of emodin in treating hepatitis B virus-associated hepatocellular carcinoma: network pharmacology and cell experiments. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1458913

BibTeX
@article{Wang2024,
  author = {Wang, Yupeng and Li, Shuangxing and Ren, Tianqi and Zhang, Yikun and Li, Bo and Geng, Xingchao},
  title = {Mechanism of emodin in treating hepatitis B virus-associated hepatocellular carcinoma: network pharmacology and cell experiments},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1458913}
}
Kostenlos starten →